Stage C adenocarcinoma of the prostate. An analysis of 551 patients treated with external beam radiation.
We retrospectively reviewed records of 551 patients with clinical Stage C prostatic adenocarcinoma treated with 60 to 70 Gy external beam radiation. Elective pelvic node irradiation was given to 247 patients (45%). Follow-up for all surviving patients ranged from 16 to 201 months (median, 6.5 years; mean, 7 years). The 5-, 10-, and 15-year uncorrected actuarial survival rates were 72%, 47%, and 27%, respectively. Disease-free survival rates were 59%, 46%, and 40% at the corresponding times. Actuarial local control rates were 88%, 81%, and 75% at 5, 10, and 15 years, respectively. Disease-free survival was adversely affected by high pathologic grade, disease fixed to the pelvic sidewall, invasion of the bladder, prior transurethral resection, hydronephrosis, and elevated serum levels of prostatic acid phosphatase and creatinine. Elective pelvic node irradiation did not improve the outcome. Complications of treatment were acceptable: minor anorectal and/or urinary symptoms, 11%; mild to moderate complications, 19%; serious problems requiring surgery, 3%. It is concluded that localized, high-energy external beam irradiation provides excellent local control of disease, low morbidity, and 5-, 10-, and 15-year survival rates that have not been rivaled by other treatment.
D000135:Acid Phosphatase / Q000097:blood; D000230:Adenocarcinoma / Q000532:radiotherapy*; D000368:Aged; D003404:Creatinine / Q000097:blood; D003556:Cystitis / Q000209:etiology; D006417:Hematuria / Q000209:etiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D010386:Pelvic Neoplasms / Q000532:radiotherapy / Q000556:secondary; D011349:Proctitis / Q000209:etiology; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000532:radiotherapy*; D011882:Radiotherapy, High-Energy; D012189:Retrospective Studies; D014554:Urination / Q000528:radiation effects
D003404:Creatinine; D000135:Acid Phosphatase